Related Experiment Video

Updated: May 13, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Ghrelin could be a candidate for the prevention of in-stent restenosis

Z W Shu1, M Yu, X J Chen

  • 1Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.

Cardiovascular Drugs and Therapy
|March 21, 2013
PubMed

Insights

In-stent restenosis (ISR) after coronary intervention is a challenge. Ghrelin, a peptide hormone, shows potential for preventing and treating ISR by addressing its multiple causes.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Vascular Biology

Background:

  • Percutaneous coronary intervention (PCI) is crucial for ischemic heart disease.
  • In-stent restenosis (ISR) remains a significant clinical challenge following PCI.
  • ISR involves complex mechanisms including inflammation, smooth muscle proliferation, endothelial dysfunction, and thrombosis.

Purpose of the Study:

  • To explore ghrelin as a potential therapeutic agent for ISR.
  • To evaluate ghrelin's multiple bioactivities relevant to ISR pathogenesis.
  • To assess ghrelin's potential for preventing and treating ISR.

Main Methods:

  • Review of existing studies on ghrelin's cardiovascular effects.
  • Analysis of ghrelin's impact on key ISR mechanisms (inflammation, proliferation, endothelial function, thrombosis).
  • Assessment of ghrelin's established roles in myocardial contractility, cardiac output, and ischemia-reperfusion injury.

Main Results:

  • Ghrelin exhibits anti-inflammatory and anti-proliferative effects on vascular smooth muscle cells.
  • Ghrelin promotes endothelial cell repair and improves vascular endothelial function.
  • Ghrelin demonstrates anti-platelet aggregation and antithrombotic properties.

Conclusions:

  • Ghrelin possesses multiple bioactivities that target the key mechanisms of ISR.
  • Ghrelin represents a promising novel therapeutic candidate for ISR prevention and treatment.
  • Further investigation into ghrelin's efficacy for ISR is warranted.

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...